Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AVTE Aerovate Therapeutics	$7.94 +8.9%	$8.62	$56.35 ▼ $105.00	$230.14M	0.95	12,438 shs	127,026 shs
IPHA Innate Pharma	$2.15 +0.2%	$1.95	$1.29 ▼ $3.51	$197.27M	0.22	13,512 shs	5,107 shs
KLRS Kalaris Therapeutics	$2.64 +3.5%	$2.68	$2.28 ▼ $24.15	$47.69M	0.49	61,540 shs	72,103 shs
MDWD MediWound	$18.41 +2.5%	$20.06	$14.14 ▼ $22.50	$194.11M	0.21	68,785 shs	75,603 shs

5G Stocks: The Path Forward is Profitable

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AVTE Aerovate Therapeutics	+15.24%	+2.45%	-28.73%	-14.25%	-86.17%
IPHA Innate Pharma	+0.23%	+1.66%	+19.83%	-9.87%	-4.24%
KLRS Kalaris Therapeutics	+3.53%	-1.86%	+1.15%	+263,999,900.00%	+263,999,900.00%
MDWD MediWound	+2.51%	-4.76%	-4.46%	+5.74%	+9.26%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AVTE Aerovate Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
IPHA Innate Pharma	2.9165 of 5 stars	3.7	5.0	0.0	0.0	0.0	1.7	0.0
KLRS Kalaris Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
MDWD MediWound	2.0343 of 5 stars	3.5	2.0	0.0	0.0	1.9	0.8	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AVTE Aerovate Therapeutics	0.00	N/A	N/A	N/A
IPHA Innate Pharma	3.33	Buy	$11.00	412.82% Upside
KLRS Kalaris Therapeutics	2.00	Hold	$3.00	13.64% Upside
MDWD MediWound	3.00	Buy	$32.25	75.18% Upside

Current Analyst Ratings Breakdown

Latest KLRS, MDWD, AVTE, and IPHA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/28/2025	IPHA Innate Pharma	BTIG Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy
7/23/2025	KLRS Kalaris Therapeutics	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Neutral	$3.00
7/23/2025	KLRS Kalaris Therapeutics	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Neutral	$3.00
6/2/2025	MDWD MediWound	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$34.00
5/22/2025	MDWD MediWound	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Buy ➝ Buy	$25.00 ➝ $31.00

(Data available from 8/7/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AVTE Aerovate Therapeutics	N/A	N/A	N/A	N/A	$3.96 per share	N/A
IPHA Innate Pharma	$21.77M	9.08	N/A	N/A	$0.11 per share	19.50
KLRS Kalaris Therapeutics	N/A	N/A	N/A	N/A	$22.47 per share	N/A
MDWD MediWound	$20.22M	9.84	N/A	N/A	$2.89 per share	6.37

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AVTE Aerovate Therapeutics	-$75.52M	-$1.70	N/A	N/A	N/A	N/A	-90.19%	-77.47%	8/11/2025 (Estimated)
IPHA Innate Pharma	-$53.53M	N/A	0.00	∞	N/A	N/A	N/A	N/A	9/17/2025 (Estimated)
KLRS Kalaris Therapeutics	-$58.77M	N/A	0.00	∞	N/A	N/A	-62.08%	-54.69%	N/A
MDWD MediWound	-$30.22M	-$2.09	N/A	N/A	N/A	-110.45%	-74.12%	-30.92%	8/14/2025 (Estimated)

Latest KLRS, MDWD, AVTE, and IPHA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	MDWD MediWound	-$0.55	N/A	N/A	N/A	$5.68 million	N/A
8/11/2025	Q2 2025	AVTE Aerovate Therapeutics	-$0.25	N/A	N/A	N/A	N/A	N/A
5/21/2025	Q1 2025	MDWD MediWound	-$0.65	-$0.07	+$0.58	-$0.07	$5.20 million	$3.96 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AVTE Aerovate Therapeutics	N/A	N/A	N/A	N/A	N/A
IPHA Innate Pharma	N/A	N/A	N/A	N/A	N/A
KLRS Kalaris Therapeutics	N/A	N/A	N/A	N/A	N/A
MDWD MediWound	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AVTE Aerovate Therapeutics	N/A	8.78	8.78
IPHA Innate Pharma	2.52	2.60	2.60
KLRS Kalaris Therapeutics	N/A	14.31	14.31
MDWD MediWound	N/A	2.15	1.99

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AVTE Aerovate Therapeutics	N/A
IPHA Innate Pharma	0.16%
KLRS Kalaris Therapeutics	66.05%
MDWD MediWound	46.83%

Insider Ownership

Company	Insider Ownership
AVTE Aerovate Therapeutics	24.90%
IPHA Innate Pharma	31.89%
KLRS Kalaris Therapeutics	74.99%
MDWD MediWound	9.20%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AVTE Aerovate Therapeutics	20	28.99 million	21.69 million	Optionable
IPHA Innate Pharma	220	92.18 million	62.79 million	Not Optionable
KLRS Kalaris Therapeutics	110	18.70 million	4.68 million	N/A
MDWD MediWound	80	10.81 million	9.81 million	Optionable

KLRS, MDWD, AVTE, and IPHA Headlines

Recent News About These Companies

MediWound Ltd. to Announce Second Quarter 2025 Financial Results and Host Conference Call on August 14

August 4 at 7:53 AM | quiverquant.comQ

MediWound to Report Second Quarter 2025 Financial Results

August 4 at 7:30 AM | globenewswire.com

Head to Head Analysis: MediWound (NASDAQ:MDWD) versus Vaxart (NASDAQ:VXRT)

August 4 at 3:35 AM | americanbankingnews.com

Here's What Could Help MediWound (MDWD) Maintain Its Recent Price Strength

July 24, 2025 | msn.com

Sargent Investment Group LLC Sells 52,500 Shares of MediWound Ltd. (NASDAQ:MDWD)

July 20, 2025 | marketbeat.com

MediWound (NASDAQ:MDWD) Lowered to "Sell" Rating by Wall Street Zen

July 19, 2025 | marketbeat.com

MediWound (NASDAQ:MDWD) Stock Price Passes Above 50 Day Moving Average - Here's Why

July 15, 2025 | marketbeat.com

MediWound Ltd. (NASDAQ:MDWD) is definitely on the radar of institutional investors who own 42% of the company

July 7, 2025 | finance.yahoo.com

MediWound Ltd. (MDWD) latest stock news and headlines - Yahoo Finance

June 26, 2025 | sg.finance.yahoo.com

Companies Like MediWound (NASDAQ:MDWD) Are In A Position To Invest In Growth

June 2, 2025 | finance.yahoo.com

MediWound’s Q1 2025: Strategic Progress Amid Financial Challenges

May 21, 2025 | tipranks.com

MediWound (MDWD) Q1 2025 Earnings Call Transcript

May 21, 2025 | msn.com

MediWound Ltd. (MDWD) Q1 2025 Earnings Call Transcript

May 21, 2025 | seekingalpha.com

MediWound (MDWD) Reports Q1 Loss, Misses Revenue Estimates

May 21, 2025 | zacks.com

MediWound Reports First Quarter 2025 Financial Results and Provides Corporate Update

May 21, 2025 | globenewswire.com

MediWound Q1 2025 Earnings Preview

May 20, 2025 | msn.com

MediWound Ltd.: Undervalued High-Growth Potential

May 16, 2025 | seekingalpha.com

MediWound Announces Publication of Phase II EscharEx® Data Demonstrating Superiority Over Collagenase in Venous Leg Ulcers

May 13, 2025 | globenewswire.com

MediWound to Report First Quarter 2025 Financial Results

May 5, 2025 | globenewswire.com

MediWound to Present New EscharEx® Data at Leading Wound Care Conferences

April 28, 2025 | globenewswire.com

Those who invested in MediWound (NASDAQ:MDWD) five years ago are up 30%

April 17, 2025 | finance.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

KLRS, MDWD, AVTE, and IPHA Company Descriptions

Aerovate Therapeutics NASDAQ:AVTE

$7.94 +0.65 (+8.92%)

As of 08/5/2025

Aerovate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. It focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial. The company was incorporated in 2018 and is headquartered in Waltham, Massachusetts.

Innate Pharma NASDAQ:IPHA

$2.14 +0.01 (+0.23%)

Closing price 08/6/2025 03:57 PM Eastern

Extended Trading

$2.10 -0.04 (-2.10%)

As of 08/6/2025 07:51 PM Eastern

Innate Pharma S.A., a biotechnology company, develops immunotherapies for cancer patients in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase III clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as well as head and neck cancer; IPH5201, a blocking antibody that is in Phase II clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway to promote antitumor immunity; IPH6401, an BCMA-targeting NK cell engager; and IPH6101, a NKp46-based NK cell engager that targets CD123 proprietary multi-specific antibody format; and IPH62, an B7-H3-targeting NK cell engager. Its products in preclinical trials are IPH43, an anti-MICA/B ADC and IPH45, an antibody drug conjugates (ADC); and IPH67, an undisclosed, multi-specific ANKET. The company has licensing and collaboration agreements with AstraZeneca, Novo Nordisk A/S, Sanofi, and Orega Biotech; and co-development and license agreement with MedImmune Limited. Innate Pharma S.A. was incorporated in 1999 and is headquartered in Marseille, France.

Kalaris Therapeutics NASDAQ:KLRS

$2.64 +0.09 (+3.53%)

As of 08/6/2025 03:59 PM Eastern

Allovir, Inc., a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company's lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus. Its preclinical and clinical development product candidates include ALVR106 for the respiratory syncytial virus, influenza, parainfluenza virus, and human metapneumovirus; ALVR109 to treat SARS-CoV-2 and COVID-19; ALVR107 for treating hepatitis B; and ALVR108. The company was formerly known as ViraCyte, Inc. and changed its name to Allovir, Inc. in May 2019. Allovir, Inc. was founded in 2013 and is based in Waltham, Massachusetts.

MediWound NASDAQ:MDWD

$18.41 +0.45 (+2.51%)

Closing price 08/6/2025 04:00 PM Eastern

Extended Trading

$18.42 +0.01 (+0.05%)

As of 08/6/2025 04:25 PM Eastern

MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in United States, Europe, and internationally. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. The company also develops EscharEx, which has completed Phase II clinical trials for the debridement of chronic and other hard-to-heal wounds; and MW005, which is in phase I/II for the treatment of low-risk basal cell carcinoma. MediWound Ltd. was incorporated in 2000 and is headquartered in Yavne, Israel.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time